Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free latanoprost + timolol versus Xalacom in open-angle glaucoma or ocular hypertension
2011-005339-15Phase 3Completed
- Sponsor
- OmniVision
- Start
- Nov 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of timolol, latanoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by OmniVision. Started Nov 2011; status: completed.
02
Drugs
timolollatanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2011-005339-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005339-15.